INFO:
Founded in December 2005, Genocore Biotech is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs.
With a total investment of about 30 million USD, Genocore Biotech now has 10 products in the pipeline with three at clinical trial/IND stage.mGenocore Biotech has a highly experienced and well-integrated expert team whose expertise covers all the key steps of mAb drug research and development.mPartnership is an intrinsic part of Genocore Biotech corporate strategy. Besides in-house Research and Development, they actively seek in-licensing, co-development or JV opportunities to strengthen its pipeline.
Genocore Biotech has established world class capability of Process & Product Development, Analytical & Quality and Manufacturing.
Genocore Biotech now has in place more than 6000 m2 of space, including R&D Lab, Process Development & Pilot Production Lab, Quality & Analytical Center, and a cGMP clinical production facility, all equipped with state of art equipment. A commercial-scale cGMP product facility is also under active planning.
Genocore Biotech Strategy
Genocore Biotech believes that it is much easier and effective to prevent rather than cure. By developing its platform for proprietary monoclonal antibody (mAbs), they will have access to the next generation of antibody accelerators and vaccines. Their products will target respiratory viruses, digestive tube viruses and seasonal pandemic viruses.